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Summary. Background: Reliable risk estimates for venous
thrombosis in families with inherited thrombophilia are scarce
but necessary for determining optimal screening and treatment
policies. Objectives: In the present analysis, we determined the
risk of a ﬁrst venous thrombotic event in carriers of a
thrombophilic defect (i.e. antithrombin-, protein C- or protein
S deﬁciency, or factor V Leiden). Patients and methods: The
asymptomatic carriers hadbeen tested prior to this study in nine
European thrombosis centers because of a symptomatic carrier
in the family, and were followed prospectively for 5.7 years on
average betweenMarch 1994 and January 2001.Annually, data
were recorded on the occurrence of risk situations for venous
thrombosis and events (e.g. venous thrombosis, death).Results:
Twenty-six of the 575 asymptomatic carriers (4.5%) and seven
of the 1118 controls (0.6%) experienced a ﬁrst deep venous
thrombosis or pulmonary embolism during follow-up. Of these
events, 58% occurred spontaneously in the carriers compared
with 43% in the controls. The incidence of ﬁrst events was 0.8%
per year (95% CI 0.5–1.2) in the carriers compared with 0.1%
per year (95%CI 0.0–0.2) in the controls. The highest incidence
was associated with antithrombin deﬁciency or combined
defects, and the lowest incidence with factor V Leiden.
Conclusions: The incidence of venous events in asymptomatic
individuals from thrombophilic families does not exceed the risk
of bleeding associated with long-term anticoagulant treatment
in the literature (1–3%).
Keywords: asymptomatic, inherited thrombophilia, venous
thrombosis.
Introduction
Venous thrombosis has an overall incidence of about 1–2 per
1000 individuals per year and is a serious disorder with
potential major complications such as death from pulmonary
embolism, recurrences and the development of a disabling post-
thrombotic syndrome [1–3]. It has been postulated that not a
single risk factor, but interaction between multiple genetic and
environmental risk factors is a prerequisite for venous throm-
bosis to develop [4–6]. Currently, several genetic risk factors are
known to increase the risk of venous thrombosis: deﬁciencies in
the anticoagulation factors protein C, protein S and anti-
thrombin, and the factor V Leiden and prothrombin G20210A
mutations [7–11]. In accordance with the multicausal nature of
thrombosis, it was found that the presence of a family history
of venous thrombosis increases the thrombotic risk in individ-
uals with protein C deﬁciency or factor V Leiden, due most
probably to the concomitant presence of other genetic or
environmental risk factors within the family [6,12,13].
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A prerequisite to determining the optimal clinical approach,
e.g. with regard to screening or (long-term) prophylactic
anticoagulant treatment in families with inherited thrombo-
philia is to deﬁne the absolute risk of venous thrombosis, and
to weigh this risk against the risk of bleeding complications
associated with prophylactic treatment. To obtain valid risk
estimates of the absolute risk of venous thrombosis in families
with inherited thrombophilia, we started the European Pros-
pective Cohort on Thrombophilia (EPCOT) study. The
EPCOT study, by combining data from nine centers, is the
largest prospective cohort of individuals with deﬁciencies of
protein C, protein S and antithrombin and factor V Leiden. In
this paper, we present data on the risk of a ﬁrst venous
thromboembolic event associated with inherited thrombophilia
in relatives of probands from thrombophilic families who were
asymptomatic at the time of inclusion in the study.
Methods
Participants
The design of the study has been described in detail previously
[14]. In short, inclusion of the participants took place between
March 1994 and September 1997 with prospective follow-up
until January 2001. Nine centers from eight countries (Austria,
France, Germany, Italy, Spain, Sweden, the Netherlands and
the United Kingdom) participated. Each center enrolled all
registered probands (ﬁrst of a family in whom thrombophilia
was detected) with a deﬁciency of protein C, protein S or
antithrombin or factor V Leiden, and their registered relatives
with one of these defects. Healthy partners or, if there were
none, friends or acquaintances of participating individuals with
inherited thrombophilia were included as controls. Controls
were excluded if they were known to have heritable thrombo-
philia, or if they were related to a participant with an inherited
thrombotic defect. Controls were, however, not tested for any
of the defects under study after study entry. All participants
gave informed consent. Data were collected at baseline, and
annually during follow-up. At study entry data were collected
on subjects’ general demographics, hereditary defect [type,
subtype (if available), levels (if available), information onDNA
testing], current medication and current risk factors for
thrombosis, history of thrombosis, obstetric history and family
history of thrombosis. The data recorded at follow-up included
the occurrence of risk situations [surgery, hospital admission,
plaster casts, prolonged bed rest (> 2 weeks), traveling
(> 8 h), details on pregnancies, medication)] and on outcome
events (e.g. venous thrombosis, hemorrhage, death). Comple-
ted forms were sent to the coordinating center with only the
patient identiﬁer’s code to protect patient conﬁdentiality.
From a total of 1626 individuals with thrombophilic defects
and 1212 control subjects, this paper includes only relatives of
probands who had not previously experienced any venous
thrombotic event [deep venous thrombosis (DVT), pulmonary
embolism (PE), or superﬁcial thrombophlebitis (STP)] before
inclusion in the study, and who did not receive long-term
prophylactic oral anticoagulant treatment during prospective
follow-up (deﬁned as treatment for at least 1 year without
interruptions). Twenty thrombophilic individuals received
long-term prophylactic oral anticoagulant treatment: 10 for
prevention of venous thrombosis and 10 for a personal history
of arterial disease. Eight controls received long-term anticoag-
ulation treatment for an arterial indication. In addition, we
only included relatives of probands tested because of venous
thrombosis or a positive family history. Families in which
thrombophilia was detected because of screening before
hormone prescription or research purposes were not included,
in an effort to stay as close as possible to the real-life situation
of an individual from a symptomatic thrombophilia family
asking a physician for advice.
Recruitment was before description of the G20210A muta-
tion in the prothrombin gene, but during prospective follow-up
we gathered information on the presence of this mutation as an
additional defect.
Quality assessment thrombophilia testing and verification
of events
The participating centers performed the various assays accord-
ing to their local protocol and participated in an external
quality assessment scheme for thrombophilia testing. For the
ﬁrst 2 years this was the quality assurance scheme developed for
the European Concerted Action on Thrombosis (ECAT/
EQAS) (Leiden) and for the subsequent years theUKNational
External Quality Assessment Service (NEQAS) (Shefﬁeld,
UK).
Per center, a local investigator veriﬁed all events in
prospective follow-up. In case of death the autopsy data were
collected, if available. An adjudication committee scored all
reported events independently after receiving all the relevant
medical information from each center, but in case of doubt or
when no consensus was reached at ﬁrst, further information
was asked for (e.g. actual test results). Committee members
were not blinded for whether a person was a thrombophilia
carrier or control, but were unaware of the type of defect of the
carriers. Venous thromboses were classiﬁed as deﬁnite venous
events when they were objectively conﬁrmed, i.e. for DVT by
ultrasound (duplex, Doppler), impedance plethysmography,
venography or leg symptoms plus deﬁnite PE, and for PE by
angiography, high probability ventilation-perfusion-scan,
spiral computerized tomography or autopsy. STPs were
considered deﬁnite events when diagnosed by a physician.
For the analysis reported here, we included only deﬁnite venous
events. Consensus on the classiﬁcation of the venous events, i.e.
that a majority of the steering committee members agreed, was
reached in 67 of the 72 (93%) reported events during
prospective follow-up (47 DVTs or PEs, 21 STPs, four major
hemorrhages). Of the remaining ﬁve events which were
classiﬁed as deﬁnite DVT or PE (n ¼ 4) or no PE (n ¼ 1),
consensus was reached after additional information was
provided (n ¼ 4) or after reconsideration (n ¼ 1). For con-
trols, immediate consensus was reached in 88% of the reported
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events (15 of 17) and in thrombophilic subjects in 95% of the
reported events (52 of 55).
Analysis and statistics
We calculated the annual absolute risk (incidence) and relative
risk of a ﬁrst DVT or PE for various groups in the cohort. The
incidence of venous thrombotic events was calculated by
dividing the number of events by the total of observation-years
(follow-up time). Follow-up time was the time between
inclusion and the event of interest, death or the last date of
follow-up (the end of the study or last date before loss to
follow-up), whichever occurred ﬁrst. A DVT or PE was
considered ﬁrst event only when not preceded by a STP. If a PE
followed a DVTwithin 3 months, these events were considered
a single event. The 95% conﬁdence intervals (95% CI) were
calculated according to a Poisson distribution for the number
of events [15]. Hazard ratios as estimation of the relative risk of
venous thrombosis were calculated by Cox-regression with
venous thrombosis as the dependent variable and presence or
absence of thrombophilia as independent variable. Center, age
(as stratum: age < 45 or ‡ 45) and sex were entered in the
Cox-regression model to adjust for center, age and sex effects.
Results
We collected prospective data on 575 relatives with a throm-
bophilic defect and 1118 controls (825 partners, 293 friends), all
without a thrombotic event prior to inclusion and not on long-
term oral anticoagulant treatment. The total follow-up time
was 3283 years in the individuals with thrombophilia (mean
5.7; range 0.2–7.3) and 6289 years in the controls (mean 5.6;
range 0.7–7.2). During follow-up, 20 thrombophilic subjects
and 64 controls were lost to follow-up (complete follow-up in
95%), and eight thrombophilic individuals and 12 controls
died. The causes of death in the carriers were heart disease
(n ¼ 3), suspected pulmonary embolism (n ¼ 1) and other
causes (n ¼ 4). Causes of death in controls were not related to
venous thrombosis (cancer (n ¼ 4), myocardial infarction
(n ¼ 4), accidents in trafﬁc or at work (n ¼ 3) or surgery
(n ¼ 1)). The main characteristics at inclusion are shown in
Table 1. A preponderance of the thrombophilic individuals
was female (62%), whereas sex was distributed more equally
among the controls.
Risk of a first event
Of the 575 thrombophilic individuals, 26 thrombophilic
subjects experienced a ﬁrst DVT or PE during follow-up
(4.5%) (one relative had a mesenteric vein thrombosis)
compared with seven of the 1118 controls (0.6%) (Table 2).
The events occurred spontaneously, i.e. did not occur after
exposure to a known acquired risk factor, in 15 thrombophilic
individuals (58%) and three controls (43%). The risk factors
present at the time of the event in the remaining 11 thrombo-
philic individuals were hospitalization (n ¼ 3), hormone
replacement therapy (n ¼ 2), infection (n ¼ 2), pregnancy
(n ¼ 2), cancer (n ¼ 1) and oral contraceptives (n ¼ 1), and in
the four remaining controls surgery (n ¼ 2), hospitalization
(n ¼ 1) and cancer (n ¼ 1). The incidence of a ﬁrst DVT or PE
was higher in the thrombophilic individuals than in the
controls, respectively, 0.8% per year (95% CI 0.5–1.2) com-
pared with 0.1% per year (95% CI 0.0–0.2) (Table 2) with a
relative risk of 9.0 (95% CI 3.8–21.1), adjusted for sex, age at
entry and center effects (crude relative risk: 7.3; 95% CI 3.2–
16.8). The incidence of a STP as ﬁrst event was 0.5% per year
(95% CI 0.3–0.8) in the thrombophilic subjects and 0.1% per
year (95% CI 0.0–0.2) in the controls (Table 2) with a relative
risk of 5.2 (95%CI 2.0–13.7), adjusted for sex, age at entry and
center effects (crude relative risk: 5.3; 95% CI 2.1–13.5).
The annual incidence of a ﬁrst DVT or PE was highest for
thrombophilic individuals with antithrombin deﬁciency (1.7%
year)1; 95%CI0.8–3.3) or combineddefects (1.6%year)1; 95%
CI 0.5–3.7) and lowest in thrombophilic individuals with the
factor V Leiden mutation (0.1% year)1; 95% CI 0.0–0.6)
(Table 2). Unfortunately, the numbers per type of defect were
too small to estimate the risks by age and sex. Our database
contained subtype information (or sufﬁcient level information
to determine the subtype) of 120 protein C deﬁcient individuals,
97 individuals with protein S deﬁciency and 76 individuals with
antithrombin deﬁciency.When we included in the analysis only
Table 1 General characteristics at inclusion
Thrombophilic
individuals Controls
All (n) 575 1118
Men (n) 214 588
Women (n) 361 530
OCC use, age 10–50 (n/total N)* 63/265 153/360
HRT use, age ‡ 50 (n/total N) 17/77 47/159
PC deﬁciency (n) 143 NA
PS deﬁciency (n) 107 NA
AT deﬁciency (n) 96 NA
FVL (n) 173a NA
Combined defects (n) 56 NA
PC-PS (n) 1 NA
FVL-PC (n) 11 NA
FVL-PS (n) 15 NA
FVL-AT (n) 6 NA
FVL-PT20210A (n) 8b NA
PT20210A-PC (n) 9 NA
PT20210A-PS (n) 4c NA
PT20210A-AT (n) 2 NA
Mean age at inclusion (years (range)) 35 (0–91) 41 (3–87)
Mean BMI (kgm)2 (range))** 23 (13–42) 24 (13–39)
Cancer ever (n (%)) 8 (1) 12 (1)
OCC ¼ oral contraceptives, HRT ¼ hormone replacement therapy,
PC ¼ protein C, PS ¼ protein S, AT ¼ antithrombin, FVL ¼ factor
V Leiden, PT20210A ¼ prothrombin G20210A, NA ¼ not applicable,
BMI ¼ body mass index. a10 were homozygous; bone was homozygous
for factor V Leiden; cone was homozygous for prothrombin
G20210 A. *The oral contraceptives contained estrogen in 34/265
(13%) thrombophilic women and 139/360 (39%) of the control women.
** Information on BMI was available for 574 thrombophilic individ-
uals and 1117 controls.
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individuals known to have subtype I (103 with protein C
deﬁciency, 68 with protein S deﬁciency and 59 with antithrom-
bindeﬁciency), the riskof amajor eventwas similar to the risk in
Table 2. The risk of thrombosis in those with a type II defect or
type III protein S defect was not lower than in those with type I
abnormalities, although the number of individuals (n ¼63)with
type II or III defects was low (results not shown).
In men with thrombophilia, the annual incidence of a ﬁrst
DVTorPEwashigher (1.4%year)1; 95%CI0.8–2.2)compared
with thrombophilic women (0.5% year)1; 95% CI 0.2–0.9)
(Table 2). In controls, the incidences of a ﬁrst DVT or PE did
notdiffer between the sexes (Table 2).Thepercentageofwomen
above the age of 50 using hormone replacement therapy was
slightly lower in thrombophilic women (22%) compared with
controls (30%), whereas a much lower percentage of women
with inherited thrombophilia used estrogen-containing oral
contraceptives (13%; age 10–50 years) compared with the
control women (39%; age 10–50 years). The incidence of a ﬁrst
DVT or PE in thrombophilic women who did not use oral
contraceptives (age 10–50 years) was 0.4% year)1 (95% CI
0.1–0.9) comparedwith0.5%year)1 (95%CI0.0–2.9) inwomen
using estrogen-containing oral contraceptives.
The ﬁrst DVT or PE occurred about 20 years earlier in the
thrombophilic individuals than in the controls (Table 2). The
mean age at onset was 40 years for individuals with protein
C-, protein S- or antithrombin deﬁciency or combined defects
and 63 years for the subject with factor V Leiden, in
comparison to 63 years in the controls (Table 2).
The risk of a ﬁrst DVT or PE was 1.0% per year (95% CI
0.6–1.6) among the 285 thrombophilic individuals who
encountered acquired risk factors during prospective follow-
up and who did not receive short-term anticoagulation during
these risk situations (i.e. surgery, hospitalization, bed rest for
more than 13 days, plaster cast, cancer, pregnancy or traveling
for more than 8 h). Table 3 shows the frequency of venous
events associated with the presence of acquired risk factors
during prospective follow-up for which no short-term pro-
phylactic anticoagulant treatment was provided. Cancer,
although the number of individuals was small, and pregnancy
appear to be the risk factors during which most secondary
venous events occurred in the thrombophilic individuals. The
incidence of a ﬁrst DVT or PE in the 156 thrombophilic
individuals who did not encounter acquired risk factors for
which they could have received short-term anticoagulation
Table 2 Incidence (% year)1) and age at onset of a ﬁrst venous thrombosis
Total subjects, n DVT/PE, n
Age onset,
years (range) Person-years, n
Incidence,
(95% CI)
Thrombophilic individuals 575 26 40 (20–65) 3194.4 0.8 (0.5–1.2)
PC deﬁciency 143 6 41 (22–65) 833.2 0.7 (0.3–1.6)
PS deﬁciency 107 5 38 (28–63) 619.1 0.8 (0.3–1.9)
AT deﬁciency 96 9 39 (21–58) 520.6 1.7 (0.8–3.3)
FVL 173 1* 63 902.1 0.1 (0.0–0.6)
Combined defects 56 5* 36 (20–62) 319.4 1.6 (0.5–3.7)
Males 214 16 37 (20–65) 1162.0 1.4 (0.8–2.2)
Females 361 10 44 (21–65) 2032.4 0.5 (0.2–0.9)
Age at inclusion 18–45 years 339 18 32 (21–47) 1880.1 1.0 (0.6–1.5)
Age at inclusion above 45 years 146 7 61 (51–65) 793.2 0.9 (0.4–1.8)
Controls 1118 7 63 (38–84) 6269.6 0.1 (0.0–0.2)
Males 588 2 58 (57–59) 3303.0 0.1 (0.0–0.2)
Females 530 5 64 (38–84) 2966.6 0.2 (0.1–0.4)
Age at inclusion 18–45 years 652 1 38 3601.8 0.0 (0.0–0.2)
Age at inclusion above 45 years 426 6 67 (57–84) 2445.7 0.2 (0.1–0.5)
DVT ¼ deep venous thrombosis, PE ¼ pulmonary embolism, CI ¼ conﬁdence interval, PC ¼ protein C, PS ¼ protein S, AT ¼ antithrombin,
FVL ¼ factor V Leiden. *All were heterozygous.
Table 3 Number of ﬁrst venous events per risk situation for which subjects did not receive short-term prophylactic anticoagulation
Thrombophilic individuals Controls
n Situations n DVT/PE, n (%) n Situations n DVT/PE, n (%)
Travel (> 8 h) 260 504* 0 (0%) 567 1244* 0 (0%)
Surgery/immobilization** 143 176 3 (2%) 290 407 2 (0%)
Plaster cast 27 33 0 (0%) 59 71 0 (0%)
Cancer 10 10 1 (10%) 17 17 1 (6%)
Pregnancies 24 28 2 (7%) 61 75 0 (0%)
DVT ¼ deep venous thrombosis, PE ¼ pulmonary embolism. *The number of follow-up years in which individuals reported to have traveled at
least once for more than 8 hours. **Immobilization is deﬁned as a hospital stay, or bed rest for at least 14 days at home. Deﬁned as malignancy
still present or developed during prospective follow-up. Nine (four thrombophilic individuals, ﬁve controls) received anticoagulation during and
after surgery for cancer.
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during prospective follow-up was, however, similar: 0.8% per
year (95% CI 0.3–1.7).
A total of 134 thrombophilic individuals (23%) received
short-term prophylactic anticoagulation during one or more
risk situations: surgery (n ¼ 95), pregnancy (n ¼ 43; 13 during
puerperium only; range start treatment during pregnancy:
weeks 5–36), plaster cast (n ¼ 13), traveling (n ¼ 9) and after
twisting a knee or an ankle (n ¼ 2). No venous events occurred
during any of these risk situations under short-term prophy-
lactic anticoagulant treatment. Of the controls, 115 (10%) also
received short-term anticoagulant treatment during risk situ-
ations: during surgery (n ¼ 107), pregnancy (n ¼ 4; 3 during
puerperium only), plaster cast (n ¼ 12), traveling (n ¼ 1) and
after twisting a knee (n ¼ 1) or during chronic enteritis (n ¼ 1).
Discussion
We conducted a large prospective follow-up study in nine
centers in eight countries on 1626 probands and relatives, and
1212 controls to obtain valid estimates of the risk of venous
thrombosis in families with inherited thrombophilia. In the
present report, we describe the risk of a ﬁrst venous throm-
boembolic event in 575 thrombophilic individuals and 1118
control subjects whowere followed-up to 7 years (mean follow-
up 5.6 years) and who were asymptomatic and not on long-
term anticoagulant treatment at study inclusion.
Among the thrombophilic individuals, the annual risk of
a ﬁrst DVT or PE was 0.8% per year. The incidence was
lowest for thrombophilic individuals with factor V Leiden
(0.1% year)1) and highest for thrombophilic subjects with
antithrombin deﬁciency (1.7% year)1), individuals with
combined defects (1.6% year)1) and men (1.4% year)1).
DVTs and PEs occurred spontaneously in 58% of the
thrombophilic individuals and 43% of the controls. The
annual risk was not increased in thrombophilic individuals
who encountered additional acquired risk situations (e.g.
surgery, immobilization, pregnancy, plaster cast) during
which no short-term anticoagulation treatment was pre-
scribed. As 134 thrombophilic individuals did receive short-
term anticoagulation during risk situations, mainly during
pregnancy and surgery, this ﬁnding could be the result of
the intention of doctors to treat those with a high risk of
venous thrombosis only in deﬁnite high-risk situations.
The strongest point of this study is its size: deﬁciencies of
natural anticoagulants are rare, and large prospective studies
are therefore scarce. We excluded events that were not
objectively conﬁrmed; as these were few and equally distri-
buted over thrombophilic individuals and controls (of the
DVTs and PEs 12% were non-deﬁnite in the carriers
compared with 14% in the controls) this could not have
affected our results. The results of this study should not be
generalized to all individuals with thrombophilia, as we
focused on asymptomatic subjects with familial thrombo-
philia, to which patient group these results apply. We have
shown previously that the risk of thrombosis is higher in
selected individuals from families with a clear familial
thrombophilia than in unselected individuals without a strong
family history, regardless of the defect [12,13]. Other studies
on the risk of a ﬁrst venous thrombotic event in carriers of a
hereditary defect [16–22] reported annual incidences of venous
thrombosis ranging from 0.4% to 2.5% for protein C
deﬁciency, 0.1% to 3.2% for protein S deﬁciency and 0.9%
to 2.9% for antithrombin deﬁciency. For factor V Leiden, the
reported incidences ranged from 0.1% to 0.7% per year
[17,19,23–25]. The risks found in the present study could have
been underestimated due to preventative measures taken by
the treating physicians, who were aware of the presence of a
thrombophilic defect, to reduce the risk of venous thrombosis.
However, the risk for individuals with single defects might
have been overestimated when they carried the prothrombin
G20210A mutation, but were not tested for this particular
mutation in our study. We were able to gather information on
the presence of this mutation as an additional defect for 360 of
the 575 thrombophilic individuals (63%).
Although the risk of a ﬁrst DVT or PE was increased in
thrombophilic individuals, the risk was still low and did not
outweigh the reported risk of 1–3% of hemorrhagic compli-
cations in patients with prolonged anticoagulant therapy with
target INRs with a lower limit of 2.0 [26,27]. Therefore, long-
term prophylactic anticoagulant treatment does not seem
beneﬁcial in asymptomatic relatives of symptomatic probands
with inherited thrombophilia, although future prophylactic
treatment options with a lower risk of bleeding might change
this. However, there might be a need for a more stringent
thromboprophylactic treatment policy during temporary
periods of increased thrombotic risk as no DVT or PE
occurred in thrombophilic individuals during risk situations
in which prophylactic anticoagulation was used. In the
thrombophilic individuals, 42% of all DVTs or PEs occurred
in the presence of a known risk situation and could therefore
have been prevented.
Whether screening or short-term prophylaxis would be
beneﬁcial is difﬁcult to conclude from our results, as the low
risk of thrombosis might be the result of screening and a policy
aimed at preventing thrombosis, as can be deduced from the
low number of women with estrogen-containing oral contra-
ceptives and the high number of women with prophylactic
anticoagulant therapy during pregnancy or puerperium.
Further studies should elucidate whether a more stringent
policy of thromboprophylaxis in risk situations could further
reduce the risk of thrombosis, which should in particular focus
on individuals with antithrombin deﬁciency and combined
defects, who had the highest risk of thrombosis.
Addendum
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